Amgen Files Update to Tavneos Label as FDA Escalates Push to Withdraw
Amgen filed a supplemental application to revise the prescribing information for its rare‑disease drug Tavneos (avacopan) as the FDA intensifies its effort to withdraw the product. The label update seeks to add new safety warnings and monitoring requirements after the agency flagged concerns about serious infections and renal complications observed in post‑marketing data. Amgen also committed to conduct a post‑approval study to assess long‑term outcomes. The move comes amid ongoing litigation and a potential market impact for the $1.5 billion drug.
Getein Biotech Q1 Profit Rises 18% to $10.7M as Revenue Hits $37.5M
Getein Biotech posted a first‑quarter profit of RMB76.3 million ($10.7 M), up 18% year‑over‑year, and revenue of RMB267.5 million ($37.5 M), a 9.6% increase. The results highlight accelerating demand for molecular diagnostics in China.
Amgen Positions MariTide as Potential ‘Best Monthly’ Obesity Drug
Amgen is positioning its bispecific antibody‑peptide MariTide as the premier monthly or less‑frequent obesity treatment. The company launched a Phase 3 MARITIME‑Switch study to evaluate switching patients from weekly GLP‑1 injections to four‑to‑six monthly doses. Phase 2 data showed up to a...
Finland’s Algorithmiq Takes Top Spot in $50M Q4Bio Challenge with Quantum Drug Simulation Milestone
Finland’s Algorithmiq won the $2 million prize in Wellcome Leap’s $50 million Q4Bio challenge, becoming the first to demonstrate an end‑to‑end quantum‑classical workflow for drug simulation on real hardware. Using up to 100 qubits on IBM’s quantum computer, the team modeled the...
Theradaptive Receives US FDA Approval to Initiate P-III Trial of OsteoAdapt SP for Spinal Fusion Procedures
Theradaptive has secured U.S. FDA approval to launch the pivotal OASIS Phase III trial evaluating its OsteoAdapt SP device as a bone‑graft alternative in transforaminal, anterior, and lateral lumbar interbody fusion (TLIF, ALIF, LLIF) procedures. The trial follows earlier studies involving...
Enzymatic DNA Synthesis Frees Synthetic Biology Design
“You should design for the biology you want to build, not for the process limitations of a supplier that’s been holding the field back.” That line from @Jason_Gammack , CEO of @AnsaBio , gets right to the heart of one...
Friday Hope: H. Erinaceus (Lion’s Mane): A Mushroom Which May Help Those Suffering From Long COVID/Spike Disease/Injury
The post reviews pre‑clinical data showing that Hericium erinaceus (Lion’s Mane) suppresses NF‑κB, COX‑2 and iNOS while activating Nrf2, thereby reducing inflammation, oxidative stress and supporting neuronal health. Mouse studies demonstrate improved mitochondrial membrane potential, ATP production and antioxidant enzyme...
AstraZeneca’s Breast Cancer Drug Fails to Earn Backing of FDA Advisory Committee
The FDA’s advisory committee voted against recommending AstraZeneca’s oral SERD camizestrant for HR⁺/HER2‑ metastatic breast cancer patients with an ESR1 mutation, citing concerns over the Phase 3 SERENA‑6 trial design. The study switched patients to camizestrant at the point of mutation...
Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent
Eli Lilly posted a strong Q1 2026, with revenue up 56% YoY to almost $20 billion, driven by $12.8 billion in GLP‑1 sales from Mounjaro and Zepbound. The FDA also approved Foundayo, the first oral GLP‑1 agonist for obesity that can be taken without...
ARCHIMED to Acquire Esperion Therapeutics in a $1.1 Billion Deal
ARCHIMED has agreed to acquire Esperion Therapeutics for approximately $1.1 billion, offering shareholders $3.16 in cash per share—a 58% premium—and a contingent value right (CVR) that could add up to $100 million based on future sales milestones. The transaction values Esperion at...
BIO on the American Road Tours Gene Therapy Hub in Ohio
BIO President John F. Crowley toured Ohio on April 28, spotlighting the state’s emerging gene‑therapy hub. Researchers at Nationwide Children’s Hospital have delivered two of the FDA’s first eight approved gene therapies for Duchenne muscular dystrophy and spinal muscular atrophy type 1....
Corcept Ties ALS Drug to Improved 2-Year Survival as Phase 3 Start Date Nears
Corcept Therapeutics reported that its experimental ALS drug dazucorilant reduced the two‑year risk of death by roughly 87% in a Phase 2 extension study, despite missing its primary motor‑function endpoint. The survival benefit was most pronounced at the 300 mg dose, though...
Seaport, Hemab Price IPOs, While Avalyn Soars in Nasdaq Debut
Three biotech companies priced their initial public offerings between Thursday and Friday, collectively raising more than $850 million. Seaport Therapeutics secured $225 million at $20 per share, while Hemab Therapeutics attracted $210 million at $18 per share. Avalyn Pharma led the pack with...
MDMA-Assisted Therapy for Depression: A Promising but Early First Step
A small open‑label proof‑of‑principle study examined MDMA‑assisted therapy in 12 adults with moderate‑to‑severe major depressive disorder. Participants received two MDMA dosing sessions spaced a month apart together with nine psychotherapy sessions. At two months, 75% of participants achieved remission and...
Interim Data Hint Weaker PFS; Selloff Caps Losses
Leerink's Daina Graybosch on $SMMT "... In our base case scenario of the company’s likely statistical design choices and enrollment timing, not hitting statistical significance at this interim suggests a degradation in PFS Hazard Ratio (HR) of ~10 percentage points...
Cue Biopharma Licenses Ascendant-221 From Ascendant Health Sciences in a ~$691.5M Deal
Cue Biopharma announced an exclusive license with Ascendant Health Sciences for Ascendant-221, an anti‑IgE monoclonal antibody aimed at allergic diseases. The agreement grants Cue worldwide rights, except Greater China, in exchange for a $15 million upfront payment and up to $676.5 million...
Approaches to Reducing Toxicity and Side Effects in Cell and Gene Therapy
Cell and gene therapies are expanding rapidly, with the market projected to exceed $9 billion in 2025 and grow over 15% annually through 2035. Safety remains a hurdle, prompting multiple strategies to curb cytokine release syndrome (CRS) and related toxicities. Companies...
FDA's ODAC Delivers One Loss, One Win for AstraZeneca
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 6‑3 against AstraZeneca’s oral SERD camizestrant in combination with CDK‑4/6 inhibitors for first‑line HR‑positive, HER2‑negative breast cancer with ESR1 mutations, citing a lack of overall survival benefit despite a 56% progression‑free survival...
FDA Taps Szarama as Acting CBER Director as Prasad’s Tumultuous Tenure Ends
Vinay Prasad is leaving his role as head of the FDA’s Center for Biologics Evaluation and Research (CBER) after a contentious tenure that included the Elevidys gene‑therapy shutdown and multiple rare‑disease therapy rejections. The agency has named his deputy, biophysicist Katherine Szarama,...
Gene Editing at Scale, Clinic Seeks Generalizable Therapies
Integrated DNA Technologies helped deliver a CRISPR therapy that rescued baby KJ Muldoon from a fatal urea‑cycle disorder, proving gene editing can correct a single disease‑causing mutation. The success highlights the field’s next hurdle: scaling personalized edits for disorders with...
Smarter AAVs Drive Gene Therapy’s Next Chapter
Gene therapy’s growth is hampered by AAV manufacturing bottlenecks, safety concerns, and high costs, prompting a wave of innovations across bioprocessing, analytics, and vector design. Companies like Thermo Fisher, PackGene, Catalent, and Asimov are deploying design‑space modeling, high‑throughput purification, and...
What’s Next in the Evolution of Standards for Biologics Development
The United States Pharmacopeia (USP) is redefining how documentary standards support biologics, moving from product‑specific monographs toward a hybrid model that blends platform‑based chapters, emerging standards, and analytical reference materials. This shift addresses the growing complexity of monoclonal antibodies, ADCs,...
90s Club Drug K Now Legit Antidepressant, PSIL up 20%
As someone who has had some fun, semi-memorable nights at NYC clubs Tunnel and Limelight in the '90s, it's hard to believe "K" has turned into a legit medication (and has $PSIL up 20% in April). That said, anyone who...
FDA Approves First Non‑antipsychotic for Dementia Agitation
⚕️ FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia 🔗https://t.co/cPNtkiSXBs 🌐 #DHPSP #Pharma #Healthcare https://t.co/KsBKc45ekk
Space-Efficient Cryogenic Sample Storage
Azenta Life Sciences introduced the CryoArc™ Pico Automated Storage System, a compact LN‑2 cryogenic platform that maintains samples at –190 °C. Designed for biobanking, clinical research, and cell‑gene therapy labs, the system integrates barcode‑driven software for sample tracking, chain‑of‑custody, and CFR 21...
Decoding Ovarian Aging to Extend Reproductive Lifespan
Ovarian aging: Mechanisms and strategies to extend reproductive lifespan Core mechanisms include genomic instability, epigenetic noise, mitochondria, inflammation, senescence & fibrosis PhD student Maria Lopez @sinclarfriends is working on it https://t.co/tuJbQb2Xcu https://t.co/K1GlXY4KsY
Identifying the Ages when Alzheimer’s Biomarkers Sharply Change
A Mayo Clinic Study of Aging analysis identified specific ages when Alzheimer’s disease biomarkers change sharply, using breakpoint regression on plasma proteins, PET imaging, hippocampal volume and cognition across 45‑90‑year‑olds. The most consistent inflection points clustered between 62 and 71...
Amgen Posts $5.6 B Q1 Revenue, Raises 2026 Guidance Amid Pipeline Gains
Amgen announced first‑quarter 2026 revenue of $5.6 billion, up 24% year‑over‑year, and raised its full‑year revenue outlook to $37.1‑$38.5 billion. The biotech giant highlighted strong growth in its lipid‑lowering and rare‑disease portfolios and noted progress on the Meritide program and a new...
Fecal Microbiota Transplantation Reduces MDM2 Expression and Risk of Liver Cancer
Researchers demonstrated that fecal microbiota transplantation (FMT) from young to old mice suppresses age‑related MDM2 overexpression and prevents liver cancer development. In the study, none of the FMT‑treated older mice developed tumors, whereas two of eight control mice did. Treated...
The Cost of Inefficiencies in Clinical Trials
Clinical trials are hampered by fragmented technology, leading to roughly 45% higher costs compared with unified platforms. Integration fees, duplicate data entry, and managing multiple vendors add significant expense and delay timelines. Unified data‑management solutions such as CRScube claim 50‑60%...
Genomics Pioneer J. Craig Venter Dies at 79, Sparking Reflection on Synthetic Biology’s Future
J. Craig Venter, the genomics visionary who helped decode the human genome and built the first synthetic bacterial cell, died on April 29, 2026, after a brief hospitalization for cancer‑treatment complications. His death, announced by the J. Craig Venter Institute,...
Zepbound Soars and Lilly Advises Patience on Foundayo
Eli Lilly reported a blockbuster first‑quarter, with revenue jumping 56% to $19.8 billion driven by soaring sales of its obesity drugs Zepbound and Mounjaro. Zepbound alone generated over $4 billion, up about 80% year‑over‑year, while Mounjaro nearly doubled to close to $9 billion. The...
How One Startup Turned Extinction Into a Multi-Billion-Dollar Science Movement
Serial entrepreneur Ben Lamm’s Colossal Biosciences, a Texas‑based de‑extinction startup, announced progress reviving the extinct Blue Buck, adding another mammal to its portfolio that already includes woolly mammoths, dire wolves and the Tasmanian tiger. The effort now spans nearly every...
How Saudi Arabia Is Developing as a Middle East Hub for Clinical Trials
Saudi Arabia is positioning itself as the Middle East’s primary hub for clinical trials, backed by robust state investment and the Vision 2030 Health Sector Transformation Programme. Healthcare spending is forecast to reach $61.05 million in 2026, while pharmaceutical sales are...
New Genetic Discovery Could Spell This Aggressive Cancer’s Downfall
UCLA researchers uncovered a genetic weakness in small cell neuroendocrine carcinoma (SCNC) by creating prostate‑derived organoid models and running genome‑wide CRISPR screens. The screens identified the transcription factor E2F3 as a synthetic‑lethal partner of RB loss, and inhibiting E2F3 halted...
This Treatment Could Reverse Osteoarthritis Joint Damage With a Single Injection
Researchers at the University of Colorado Boulder have secured a $33.5 million ARPA‑H grant to develop a regenerative osteoarthritis therapy that could reverse joint damage with a single injection. The approach uses a controlled‑release particle system to deliver an approved drug...
Comparative Assessment of Brassica Nigra Seed and Its Sprout Ethanolic Extracts Against Paracetamol-Induced Hepatotoxicity in Rats: Insight Into Antioxidant and...
Researchers compared ethanolic extracts of Brassica nigra (black mustard) seeds and sprouts for protecting rat livers against a high‑dose paracetamol challenge. Rats received 500 mg/kg body weight of each extract for 21 days, with silymarin (100 mg/kg) as a reference drug. Both extracts...
Solvent‐Free Preparation of Pharmaceutically Active Diindolylmethane Derivatives by Stable Triple‐Interpenetrated Heterometallic‐Organic Frameworks With Sc‐Pd/Pt Synergistic Sites
Researchers reported a one‑pot synthesis of triple‑interpenetrated heterometallic‑organic frameworks (HMOFs) containing Sc‑Pd or Sc‑Pt synergistic sites. The resulting ScPd‑INA, ScPt‑INA and ScPt‑MCA catalysts achieved up to 99% conversion in solvent‑free Friedel‑Crafts alkylation of diindolylmethane (DIM) precursors. Single‑crystal X‑ray diffraction confirmed...
STAT+: Her Daughter Mila Got a Bespoke Medicine. Now She’s Starting a New Biotech to Make More
Julia Vitarello, whose eight‑year‑old daughter Mila was treated with a tailor‑made gene therapy, announced she is launching a new biotech to scale individualized medicines. Her previous company, EveryONE Medicines, folded after FDA guidance on custom therapies proved insufficient for investors....
Orf Genetics on Cutting Growth Factor Costs and Supplying Cultivated Meat Sector
Orf Genetics, an Icelandic biotech firm, is cutting cultivated‑meat growth‑factor costs by producing them in barley instead of traditional E. coli systems. The barley‑based platform delivers comparable bioactivity at a fraction of the price and is already used by roughly 150...
LEO Pharma to Acquire Replay for Rare Skin Disease Gene Therapy Platform
LEO Pharma has signed a definitive agreement to acquire gene‑therapy specialist Replay for an upfront cash payment of $50 million, with additional milestone fees and tiered single‑digit royalties. Replay brings a herpes simplex virus (HSV) platform that delivers large therapeutic genes...
Scientists Build Drug-Carrying DNA Robots to Target Diseases
Scientists have engineered microscopic DNA robots that can carry therapeutic payloads and seek out viruses, acting as nano‑surgeons within the bloodstream. By applying origami‑inspired rigid joints and flexible components, the robots achieve nanometer‑scale precision. Movement is programmed through DNA strand...
Pinnacle Food Group Eyes Open-Source Precision Fermentation Hub in Hong Kong
Canadian biotech firm Pinnacle Food Group has signed a non‑binding MoU with the Open Yeast Collection and Bioboost Synbio Consulting to explore an Open Yeast Platform hub in Hong Kong‑Shenzhen Innovation and Technology Park. The hub would combine an open‑access...
Beacon Biosignals Is Mapping the Brain During Sleep
Beacon Biosignals has launched an FDA‑cleared, lightweight EEG headband that records clinical‑grade brain activity while users sleep at home. The device’s machine‑learning platform extracts detailed sleep‑stage metrics and subtle architecture changes, supporting more than 40 global clinical trials for conditions...
Food Timing May Shape How T Cells Respond to Infection and Therapy
A Nature study shows that lipids released after a meal rapidly reprogram T‑cell metabolism, boosting glucose uptake, mitochondrial mass and cytokine production. Researchers observed these effects in both human donors and mice, with fed‑state T cells showing enhanced proliferation and...
![[Comment] GLP-1 Therapies: An Emerging Approach for Alcohol Reduction?](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/f628ae5758874c46e9810dd10e2c007b.webp)
[Comment] GLP-1 Therapies: An Emerging Approach for Alcohol Reduction?
Alcohol use disorder (AUD) remains one of the world’s most prevalent yet undertreated conditions, with fewer than 2 % of affected Americans receiving an FDA‑approved medication. Recent randomized trials of once‑weekly GLP‑1 receptor agonists, especially semaglutide, have demonstrated statistically significant reductions...
![[Comment] HPV Vaccine Scale-Up Is Key to Curb Rising Cervical Cancer Inequalities](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/d5dae544601ad09d68c3dce84ec5011b.webp)
[Comment] HPV Vaccine Scale-Up Is Key to Curb Rising Cervical Cancer Inequalities
Despite advances in high‑income nations, cervical cancer deaths remain heavily concentrated in low‑ and lower‑middle‑income countries, where screening is scarce. Modeling studies show that scaling up HPV vaccination, especially with single‑dose regimens, could dramatically narrow these gaps. However, political and...
New Genetic Risk Report Reveals Hidden Heart Disease Risk Before Symptoms Appear
A JACC study validated an integrated polygenic risk‑score (PRS) panel for eight cardiovascular conditions using 245,394 All of Us participants and 53,306 Mass General Brigham Biobank members. The report stratifies risk, with the top 10% showing a 41‑fold odds for...
Gentler Treatment Improves Survival in Children with Relapsed Leukemia
A UK‑wide trial (UKALL Rel2020) tested a gentler regimen for children and young adults with relapsed acute lymphoblastic leukemia, using reduced‑intensity chemotherapy followed by the targeted immunotherapy blinatumomab. The study enrolled 188 patients across 25 centres and achieved a 92%...
Blood Test Pinpoints Amyloid‑to‑tau Transition in Alzheimer’s
Tracking the turning point in Alzheimer’s disease A blood biomarker reveals the mechanistic shift from amyloid to tau pathology https://t.co/p2UfYwgBHW https://t.co/Kuu82UPrFv